[
    "{\"step_by_step_thinking\": \"The patient's HIV infection is not responding to the current antiretroviral therapy, as indicated by the decrease in CD4 count and increase in viral load. The new drug in the regimen is described as preventing viral DNA synthesis without undergoing intracellular phosphorylation. This is a characteristic of integrase inhibitors, which block the integration of the viral DNA into the host cell's genome. Efavirenz is a non-nucleoside reverse transcriptase inhibitor, Ritonavir is a protease inhibitor, Lamivudine is a nucleoside reverse transcriptase inhibitor, and Raltegravir is an integrase inhibitor.\", \"answer_choice\": \"C. Raltegravir\"}"
]